ESR1 and neoplasm: The PaSSS-based combination for EGFR+ MDA-MB-468 TNBC cell line, comprising of anti-EGFR, anti-ER and anti-MAPK inhibitors stopped the MDA-MB-468 tumor growth, but not the growth of another TNBC, MDA-MB-231 cells, the PaSSS of which did not include EGFR.